Compare AU
Compare VETH vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vanguard Ethically Conscious Australian Shares ETF (VETH) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
VETH | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 797 | 82 |
Median incremental investment | $993.50 | $619.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,312.45 | $1,323.41 |
Average age group | 26 - 35 | > 35 |
Key Summary
VETH | CURE | |
|---|---|---|
Strategy | VETH.AX was created on 2020-10-12 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Ethically Conscious Australian Shares ETF seeks to track the return ofthe FTSE Australia 300 Choice Index before taking into account fees, expenses and tax. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Commonwealth Bank of Australia (10.17 %) CSL Ltd. (9.69 %) National Australia Bank Ltd. (5.54 %) | Natera Inc (3.41 %) Incyte Corp (2.94 %) Gilead Sciences Inc (2.88 %) |
Top 3 industries | Financials (34.37 %) Materials (18.25 %) Health Care (13.54 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | Australia (98.46 %) New Zealand (1.54 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.17 % | 0.45 % |
Key Summary
VETH | CURE | |
|---|---|---|
Issuer | Vanguard | Global X |
Tracking index | FTSE Australia 300 Choice Index | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.17 % | 0.45 % |
Price | $66.07 | $49.94 |
Size | N/A | $38.065 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 3.73 % | 4.24 % |
Market | ASX | ASX |
First listed date | 13/10/2020 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
VETH | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 797 | 82 |
Median incremental investment | $993.50 | $619.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,312.45 | $1,323.41 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
VETH | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
VETH | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |